Navigation Links
FDA Approves New Treatment for Type 2 Diabetes
Date:5/2/2011

SILVER SPRING, Md., May 2, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Tradjenta (linagliptin) tablets, used with diet and exercise, to improve blood glucose control in adults with Type 2 diabetes.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

People with Type 2 diabetes do not produce or respond normally to insulin, a hormone that regulates the amount of glucose in the blood. Over time, high blood glucose levels can increase the risk for serious complications, including heart disease, blindness, and nerve and kidney damage.

"This approval provides another treatment option for the millions of Americans with Type 2 diabetes," said Mary Parks, M.D., director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research. "It is effective when used alone or when added to existing treatment regimens."

Type 2 diabetes is the most common form of the disease, affecting between 90 percent and 95 percent of the 24 million people in the United States with diabetes. Tradjenta increases the level of hormones that stimulate the release of insulin after a meal by blocking the enzyme dipeptidyl peptidase-4 or DPP-4, which leads to better blood glucose control.

Tradjenta was demonstrated to be safe and effective in eight double-blind, placebo-controlled clinical studies involving about 3,800 patients with Type 2 diabetes. The studies showed improvement in blood glucose control compared with placebo.

Tradjenta has been studied as a stand-alone therapy and in combination with other Type 2 diabetes therapies including metformin, glimepiride, and pioglitazone. Tradjenta has not been studied in combination with insulin, and should not be used to treat people with Type 1 diabetes or in those who have increased ketones in their blood or urine (diabetic ketoacidosis).

Tradjenta will be dispensed with an FDA-approved Patient Package Insert that explains the drug's uses and risks. The most common side effects of Tradjenta are upper respiratory infection, stuffy or runny nose, sore throat, muscle pain, and headache.

Tradjenta is marketed by Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Conn., and Indianapolis-based Eli Lilly Co.

For more information:

Type 2 Diabetes

http://www.nlm.nih.gov/medlineplus/ency/article/000313.htm

Approved Drugs: Questions and Answers

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm

Media Inquiries: Morgan Liscinsky, 301-796-0397; morgan.liscinsky@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Zytiga for Late-Stage Prostate Cancer
2. FDA Approves Updated, Clarified Indication for Use for iFuse Implant System®
3. FDA Approves Lamictal®XR™ (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients
4. FDA Approves the First Vaccine to Prevent Meningococcal Disease in Infants and Toddlers
5. FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis
6. FDA Approves New Medical Device for Form of Brain Cancer
7. FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors
8. FDA Approves Horizant To Treat Restless Legs Syndrome
9. FDA Approves New Treatment for Rare Form of Thyroid Cancer
10. FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Groups Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma
11. FDA Approves Hyperopia Application for the MEL 80 Excimer Laser from Carl Zeiss Meditec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Calif. , March 27, 2017  Cryoport, Inc. ... that it intends to offer shares of common stock ... registration statement on file with the Securities and Exchange ... and other conditions, and there can be no assurance ... completed, or as to the actual size or terms ...
(Date:3/27/2017)... March 27, 2017  A new survey ... that Medicare,s Competitive Bidding Program (CBP) significantly reduced beneficiary ... The lack of choice forces beneficiaries to switch to ... health consequences. AADE,s survey is the ... and others pointing out the inherent problems with the ...
(Date:3/27/2017)... 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus MD" ... MD is pleased to announce it has received conditional ... the TSX Venture Exchange.  Receiving the ... of significant achievements for Invictus-MD. Some of which include: ... AB Laboratories Inc. ("AB Labs"), a Licensed Producer under ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... AutismOne announced the ... Association of Integrative Medicine and available for application on Saturday, May 27, 2017, ... Conference in Colorado Springs. , Ed Arranga, president of AutismOne, stated: "Many of ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... Association’s Tri-State Camp Conference in Atlantic City March 13-16, was a busy spot ... team of professional staff discussed strategies for preventing outbreaks among camp communities during ...
(Date:3/28/2017)... ... ... Oily skin is a common and unwelcomed occurrence in people of all ages, genders and ... to the discussion of dealing with excess skin oil. “Oily skin is a challenge to ... can help remove the oily shine while keeping the skin fresh and clean,” says Dr. ...
(Date:3/28/2017)... ... 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s ... things that his parents and teachers had asked of him that he had neglected to ... to defy the Almighty Creator. There were some who would have felt themselves to be ...
(Date:3/27/2017)... ... March 27, 2017 , ... The respected ... who want straight teeth without the extensive time commitment and aesthetic disadvantages of ... acquiring a referral. A custom-designed series of virtually invisible aligners are created for ...
Breaking Medicine News(10 mins):